Wave Life Sciences (WVE) announced clinical trial application, CTA, approval and initiation of the Phase 1 INLIGHT clinical trial of WVE-007 in obesity. WVE-007 is a long-acting GalNAc-conjugated small interfering RNA, siRNA, that targets INHBE messenger RNA. INHBE is a genetically validated target that provides a novel approach for healthy weight loss. Wave expects to deliver proof-of-concept clinical data in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences Advances in RNA Editing Innovations
- Wave Life Sciences announces expected 2025 milestones
- Intellia Therapeutics price target lowered to $48 from $60 at Evercore ISI
- 3 Best Stocks to Buy Now, 12/25/2024, According to Top Analysts
- Wave Life Sciences announces submission of CTA for WVE-007
Questions or Comments about the article? Write to editor@tipranks.com